NASDAQ OMX

Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting

Del

GOTHENBURG, Sweden and London, 2015-11-12 13:00 CET (GLOBE NEWSWIRE) -- Albireo Limited, a clinical-stage biopharmaceutical company developing through its operating subsidiary novel bile acid modulators to treat rare pediatric liver diseases, NASH, and gastrointestinal disorders, announced today that Albireo scientists will present a poster of clinical data for A4250 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held from November 13 through November 17 in San Francisco, California. A4250, Albireo's lead product candidate, is being developed as a treatment for rare pediatric liver diseases and nonalcoholic steatohepatitis (NASH).

Albireo's poster, titled "The Ileal Bile Acid Transporter Inhibitor A4250 Modulates Bile Acid Synthesis and Decreases Serum Bile Acids," is scheduled to be presented on Sunday, November 15, 2015. The poster includes data from a double-blind Phase 1 single and multiple ascending dose clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamics of A4250 in healthy volunteers.

"Our data to be presented at the AASLD meeting highlight the promise of A4250 in reducing serum bile acids, which are typically elevated in cholestatic liver disease and often associated with severe liver damage, as well as the compound's minimal systemic exposure at therapeutically relevant doses and favorable safety and tolerability profile," said Ron Cooper, Albireo's President and Chief Executive Officer. "Enrollment continues in two ongoing Phase 2 clinical trials of A4250, one in pediatric cholestatic pruritus and one in primary biliary cirrhosis."

About A4250

A4250 is a first-in-class product candidate in development for rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), and nonalcoholic steatohepatitis (NASH). A4250 is a highly potent and selective inhibitor of the ileal bile acid transporter that acts locally in the gut, has minimal systemic exposure and is excreted substantially intact, resulting in a reduced risk of systemic side effects and undesirable drug-drug interactions. A4250, which is currently being evaluated in Phase 2 clinical trials in pediatric cholestatic pruritus and primary biliary cirrhosis, has been granted orphan drug designation in the United States and the European Union for PFIC, as well as certain other cholestatic liver diseases.

About Albireo

Albireo Limited is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel locally acting bile acid modulators to treat diseases in which there is high unmet medical need, including rare pediatric liver diseases, nonalcoholic steatohepatitis (NASH), and debilitating gastrointestinal disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008 and is backed by top-tier life science investors such as Phase IV Ventures, TPG Biotech, TVM Capital Life Science and Aberdeen Asset Management, as well as AstraZeneca.

Albireo Limited is incorporated and registered in England and Wales, and its wholly owned subsidiaries are located in Gothenburg, Sweden (including its operating subsidiary Albireo AB) and Boston, Massachusetts. For more information on Albireo, please visit www.albireopharma.com.

Albireo is a registered trademark of Albireo AB in key pharmaceutical markets in Europe.

         CONTACT:
         Albireo Contact:
         Jan Mattsson
         Chief Operating Officer
         Tel: +46 31 741 14 80
         info@albireopharma.com

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

TEAM Industries Announces New Innovative Transmission Incorporating Fallbrook's NuVinci® CVP Technology24.10.2017 02:25Pressemelding

Design is ready for vehicle implementation in powered recreational and utility vehicles CEDAR PARK, TEXAS and BAGLEY, MINNESOTA, Oct. 23, 2017 (GLOBE NEWSWIRE) -- TEAM Industries (TEAM) and Fallbrook Technologies Inc. (Fallbrook) announced today that TEAM has a production-ready innovative new transmission design for all-terrain vehicles (ATV) and utility task vehicles (UTV) available to OEMs for vehicle implementation. The transmission incorporates Fallbrook's NuVinci® continuously variable planetary (CVP) technology. NuVinci is a platform technology for a new class of continuously variable transmissions (CVT). It utilizes spheres instead of gears or belts, and can be deployed in a wide variety of applications to improve performance and/or system efficiency. TEAM has an exclusive licensing agreement with Fallbrook for the use of NuVinci CVP technology in North America and Europe in electric and gasoline light vehicle applications. TEAM is also workin

Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging24.10.2017 01:00Pressemelding

MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation (MTR), is pleased to announce that it has entered into a development and commercialization partnership with Advanced Nuclear Medicine Ingredients SA (ANMI). Under the terms of the agreement, Telix and ANMI will partner to commercialise ANMI's 68Ga-HBED-CC-PSMA (68Ga-PSMA-11) kit (Kit), a proven technology used to accurately image and stage metastatic prostate cancer, in the US market. Telix will also offer the Kit on a worldwide basis as a companion diagnostic imaging agent to the Company's prostate cancer therapeutic (TLX-591)1. The agreement includes filing a Drug Master File (DMF) for the Kit, and completion of the necessary clinical trials to obtain marketing authorisatio

Telix Pharmaceuticals Limited Launches $50 Million Underwritten Initial Public Offering (ASX: TLX)23.10.2017 23:00Pressemelding

MELBOURNE, Australia, Oct. 23, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, the Company), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), is pleased to announce the opening of its Initial Public Offering (IPO or Offer) to raise A$50 million. The IPO is an offer by Telix for the issue of 77.0 million shares at $0.65 per share and is fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited. The IPO has been strongly supported by the Company's existing shareholders, which include both industry partners and domestic institutional investors, such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Allan Moss and Alium Capital Management. With this Offer, Telix will further strengthen its Australian and international institutional shareholder base, including the addition of Fidel

Brookfield Asset Management Notice of 2017 Q3 Results Conference Call and Webcast23.10.2017 17:03Pressemelding

Date:    Thursday, November 9, 2017 Time:   11:00 a.m. (Eastern Time)  BROOKFIELD, News, Oct. 23, 2017 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Asset Management's 2017 Third Quarter Conference Call & Webcast on Thursday, November 9, 2017 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on November 9th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com "News - Press Releases." The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-800-319-4610 toll free in North America, or for overseas calls please dial 1-604-638-5340 at approximately 10:50 a.m. The Conference Call will also be Webcast live at http://servic

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines23.10.2017 13:00Pressemelding

LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, is pleased to announce the receipt of a $7.3 million contract from the Biomedical Advanced Research and Development Authority (BARDA) for the implementation of a rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government's responsiveness to future pandemic threats. When combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection system, the rapid sterility test will result in faster release of vaccines and other sterile products. Timely delivery of these products carries multiple public benefits, principally in facilitating rapid responses to pandemic or emerging infections, agents of bioterrorism, and availability of life saving medicines. "Our continuing relationship with BARDA demonstrate

Xehar Fashion App Ditches the Shopping Cart and Picks Up Speed23.10.2017 12:00Pressemelding

New fast fashion app will shorten the checkout time by removing the shopping cart altogether. PLAYA VISTA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Fashion tech company Xehar, today announces they will be removing the shopping cart from their Xehar shopping app. For millennial women shoppers who are interested in fashion but are frustrated with the online shopping experience, the Xehar app is their solution. "Xehar has found a way to increase conversion for app purchases by simply removing the function of the shopping cart," says Hadari Oshri, founder and CEO of Xehar. "Within the app, users select complete outfits and purchase with ease. By removing the shopping cart we are reducing friction and speeding up the checkout process." A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c58ce496-70e7-4675-8f59-3e39725708c4 Website and app owners deal with the reality of shopping cart abandonment

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom